Intergroup RTOG 98-11: A phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal.


4009 Background: An ∼65% 5-year disease-free-survival (DFS) rate from 5-FU/mitomycin/radiation for anal carcinoma needs improvement. METHODS A phase III randomized trial compared 5-FU (1,000mg/m2 days 1-4 and 29-32) plus mitomycin (10mg/m2 days 1 and 29) and radiation (45 to 59 Gy) (Arm A) to 5-FU (1,000mg/m2 days 1-4, 29-32, 57-60 and 85-88) plus… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.